

<http://www.pjbs.org>

PJBS

ISSN 1028-8880

**Pakistan
Journal of Biological Sciences**

ANSI*net*

Asian Network for Scientific Information
308 Lasani Town, Sargodha Road, Faisalabad - Pakistan

Inducible Clindamycin Resistance in *Staphylococcus aureus*: A Cross-Sectional Report

Mohammad Rahbar and Masoud Hajia

Department of Microbiology, Reference Laboratories of Iran, Bo-Ali Hospital, Damavand Ave, Iran

Abstract: The incidence of inducible clindamycin resistance were studied in Milad Hospital of Tehran, Iran. Of 175 isolates of *S. aureus* 17(9.7%) isolates showed inducible clindamycin resistance. Of 17 inducible clindamycin isolates of *S. aureus*, 11 strains were methicillin resistant *S. aureus* (MRSA) and 6 isolates were methicillin susceptible *S. aureus* (MSSA). All isolates were susceptible to vancomycin and linezolid. We conclude that it is necessary to perform D-test for detection of inducible clindamycin in staphylococci in routine laboratory practices.

Key words: *Staphylococcus aureus*, inducible clindamycin resistant, D-test

INTRODUCTION

Methicillin-resistant *Staphylococcus aureus* (MRSA) infections have become common among hospitalized and nonhospitalized patients. Optimal therapy for MRSA infections has yet to be determined, but this matter is complicated by the possibility of inducible macrolide-lincosamide-streptogramin B resistance (Goyal *et al.*, 2004; Patel *et al.*, 2006).

Macrolide antibiotics are bacteriostatic agents that inhibit protein synthesis by binding reversibly to 50S ribosomal subunits of susceptible organism. Target site modification is the most common mechanism of acquired resistance to macrolides, lincosamide and streptogramin B (MLS_B) antibiotics in *Staphylococcus aureus* and confer cross-resistance to the MLS antibiotics (the So-called MLS_B phenotype) MLS_B resistance can be either constitutive (MLS_B^c) or inducible (MLS_Bⁱ). When it is inducible, bacteria often test resistant to erythromycin but susceptible to clindamycin (Schreckenberger *et al.*, 2004; Delialioglu *et al.*, 2005; Steward *et al.*, 2005; Zelazny *et al.*, 2005).

Fiebelkorn *et al.* (2003) have recently described a practical disk diffusion method for detection of inducible clindamycin resistance in *S. aureus* in clinical specimens. This test involve the placement of an erythromycin and clindamycin disk in close proximity 15-26 mm apart on a Mueller-Hinton agar plate This method has been standardized recently by Clinical Laboratories Standard Institute (CLSI M100-S15 2005) and known as D-test.

Because the rate of inducible clindamycin resistance (MLS_B) in our country is unknown, the objective of this

study was (i) to determine the rate of inducible clindamycin in both methicillin resistant and susceptible strains of *S. aureus* in Milad Hospital of Tehran; (ii) To introduce a simple and practical double disk diffusion agar inhibitory assay or double disk diffusion method (D-test) for detection inducible clindamycin resistance in clinical microbiology laboratories in our country.

MATERIALS AND METHODS

One hundred and seventy five isolates of *S. aureus* comprising, methicillin-resistant *S. aureus* (MRSA) and methicillin susceptible *S. aureus* (MSSA) isolates were obtained from microbiology laboratory of Milad hospital of Tehran, Iran. Isolated microorganisms were identified by the conventional microbiological methods including colony morphology, Gram stain, catalase, slide and tube coagulase tests and DNase (Kloos and Bannerman, 1995). Methicillin resistance was detected according to the recommendation of national committee for clinical laboratory standards (NCCLS). Briefly by using 1 µg of oxacillin disk (Mast diagnostic group) on a swab inoculated Muller-Hinton agar plate supplemented with 2% NaCl and incubating at 35°C for 24 h. Susceptibility testing to the other antibiotics performed by disk diffusion method as recommended by NCCLS, 2004). The antibiotics used were penicillin (10IU), linezolid (30 µg) mupirocin (5 µg) vancomycin (30 µg) and trimethoprim-sulfamethoxazole (1.25-23.75 µg).

To detect inducible clindamycin resistance, 15 µg erythromycin and 2 µg clindamycin disks were placed on a Mueller-Hinton agar plate at a distance 15-20 mm for

Table 1: MLS_B resistance phenotype of *S. aureus*

Isolates	Constitutive MLS _B resistance (n%)	Inducible MLS _B resistance n (%)	MS phenotype n (%)
MRSA (53)	25 (47.6)	12 (22.6)	8 (15)
MSSA (122)	2 (1.6%)	5 (4.0)	1 (0.8%)
<i>S. aureus</i> (175)	27 (17.1)	17 (10.8%)	9 (5.7%)




Fig. 1: Double-disk diffusion test (D-test) demonstrating erythromycin disk (E) induction of clindamycin resistance; a blunting of the zone inhibition around the clindamycin (CL) disk is produced a D shape

double-disk diffusion test. If there is inducible clindamycin resistance, the erythromycin will diffuse through the agar and resistance to clindamycin will be induced, resulting flattening of clindamycin inhibition adjacent to erythromycin disk and giving D-shape to the zone. Strains were resistant to both erythromycin and clindamycin were defined as showing constitute MLSB resistance, those showing flattening of the clindamycin zone adjacent to the erythromycin disk were defined as having inducible MLSB and those were resistant to erythromycin and sensitive to clindamycin were defined as showing the MLSB phenotype (Fiebelkorn *et al.*, 2003; CLSI, 2006). An example of inducible clindamycin is shown in Fig. 1.

RESULTS

Of the 175 isolates *S. aureus*, there was 85 (48.5%) urine, 37(21.4%) wound, 22(12.5%), tracheal tube aspirates, 9(5.1%), blood and 22(12.5%) isolates from other biological samples. We found that 17(9.7%) isolates showing inducible clindamycin, resistance. Of the 17 inducible clindamycin resistant isolates of *S. aureus* there were 11 isolates demonstrating methicillin resistant (MRSA) while 6 isolates methicillin susceptible (MSSA). It was also found that there were 27 isolates showing

resistant to both erythromycin and clindamycin (constitutive resistant) and finally 9 isolates were resistant to erythromycin and susceptible to clindamycin (Table 1).

Of 175 isolates of *S. aureus* 53 (35%) isolates were resistant to methicillin (MRSA). All isolates were susceptible to linezolid and vancomycin, 1.6% were resistant to mupirocin and 28.5% of isolates were resistant to trimethoprim-sulfamethoxazole.

DISCUSSION

Accurate results of antibiotic susceptibility tests are important for deciding appropriate and effective therapy of infections caused by *S. aureus*. Applying proper disk placement on routine disk diffusion method can detect inducible clindamycin resistance. However clinical microbiology laboratories should report *in vitro* inducible clindamycin resistance in *S. aureus* isolates and that clinician should be aware of the potential for clinical failure when clindamycin is used to treatment of such infections due to *S. aureus* (MRSA or MSSA) with *in vitro* inducible clindamycin resistance (Sibery *et al.*, 2003; Levin *et al.*, 2005).

In this study we have found that resistance to erythromycin and clindamycin were higher in MRSA in comparison of MSSA strains (Table 1). The proportion of inducible clindamycin resistance in MRSA was double in comparison to MSSA Lim *et al.* (2002) reported that inducible clindamycin resistance was 14.6% in erythromycin resistant *S. aureus* isolates and 9.6% in erythromycin resistant coagulase-negative staphylococci isolates by employing double-disk diffusion methods in a Korean hospital population. In other study, Hamilton-Miller and Shah (2000) have reported that in *S. aureus* isolates, 12% had inducible and 2% had constitutive MLS resistance and 1% had the MS phenotype. In their study 31% of coagulase-negative staphylococci strains had inducible, 11% had constitute MLS resistance and 13% had the MS phenotype. In study from Turkey it was found that 7.6% strains of *S. aureus* had inducible clindamycin resistance whilst 24.7% had constitutive MLS. By the contrary, there was not MS phenotype (Delialioglu *et al.*, 2005). In a study by Kader *et al.* (2005) from Saudi Arabia of the 291 erythromycin resistant Staphylococci 82 (28%) isolates demonstrated

constitutive clindamycin resistance [2 (2.9%) *S. aureus*, 43 (53%) MRSA and 37 (26%) coagulase-negative staphylococci]. Inducible clindamycin resistance was demonstrated in 113 (38.8%) of Staphylococcal isolates. In study from United States America Schreckenberger *et al.* (2004) have shown that, the incidence of inducible clindamycin resistance at two hospital (an inner-city hospital and a suburban community hospital) were 7 and 12% for MRSA. The corresponding figures MSSA were, 20 and 19%, respectively. In the other studies (Bueno-Chavez *et al.*, 2005) the rate of inducible (MLS_B) have ranged from 8 to 95% in different times in the United States. In our study 10.8% isolates of were inducible MLS resistance, 17.15% constitutive and 5.7% MS phenotype. The reasons for the differences between the present study and that Schreckenberger *et al.* (2004) are, inducible clindamycin resistance may vary by region, age group and methicillin susceptibility. (MRSA or MSSA) with *in vitro* inducible clindamycin resistance.

Clindamycin is a useful drug in the treatment of skin and soft-tissue infections and serious infections caused by staphylococcal species as well as anaerobes Accurate susceptibility data are important for appropriate therapy decisions. In staphylococci, *in vitro* susceptibility testing for clindamycin may indicate false susceptibility by the broth microdilution method and by disk diffusion testing with erythromycin and clindamycin disks in nonadjacent position however if inducible resistance can be reliably detected on a routine basis in clinically significant isolates, clindamycin can be safely and effectively used in those patients with true clindamycin-susceptible strains (Fiebelkorn *et al.*, 2003). This study detected the rate of inducible clindamycin in *S. aureus* in our hospital, we also introduced a simple reliable method to detect inducible clindamycin resistance to clindamycin in erythromycin-resistant isolates of *S. aureus*.

ACKNOWLEDGMENT

We thank all of laboratory medical technologist in Milad Hospital for assistance in collecting clinical isolates and J. Nourooz-Zadeh for her review of this manuscript and many valuable suggestions.

REFERENCES

Bueno-Chavez, S., B. Bozdogan, K. Katz, K.L. Bowlware and N. Cushion *et al.*, 2005. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant *Staphylococcus aureus* in Dallas, Texas. Antimicrobiol. Agents Chemother., 49: 2283-2288.

Clinical and Laboratory Standards Institute (CLSI), 2006. Performance Standards for Antimicrobial Disk Susceptibility Tests; 16th International Supplement. CLSI Document M100-S16. Wayne, PA, USA.

Delialioglu, N., G. Aslan, C. Ozturk, V. Baki and G. Emekdas, 2005. Inducible clindamycin resistance in staphylococci isolated from clinical samples. Jpn. J. Infect Dis., 58: 104-106.

Fiebelkorn, K.R., S.A. Crawford, M.L. McElmeel and J.H. Jorgensen, 2003. Practical disk diffusion method for detection of inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci. J. Clin. Microbiol., 41: 4740-4744.

Goyal, R., N.P. Singh, V. Manchanda and M. Mathur, 2004. Detection of clindamycin susceptibility in macrolid resistant phenotypes of *Staphylococcus aureus*. Ind. J. Med. Microbiol., 22: 241-254.

Hamilton-Miller, J.M.T. and S. Shah, 2000. Patterns of phenotypic resistance to the macrolid-lincosamide-ketolide-streptogramin group of antibiotics in Staphylococci. J. Antimicrob. Chemother., 46: 941-949.

Kader, A.A., A. Kumar and A. Krishna, 2005. Induction of clindamycin resistance in erythromycin-resistant, clindamycin susceptible and methicillin-resistant clinical Staphylococcal isolates. Saudi. Med. J., 26: 1914-1917.

Kloos, W.E. and T.L. Bannerman, 1995. Staphylococcus and Micrococcus Murray, E.J., M.A. Baron, M.A. Faller, F.C. Tenover and R.H. Tenover (Eds.), Manual of Clinical Microbiology. 6th Edn. ASM Press, Washington. D.C., pp: 282-298.

Levin, T.P., B. Suh, P. Axelrod, A.L. Truant and F. Tomas, 2005. Potential clindamycin resistance in clinical susceptible erythromycin-resistant *Staphylococcus aureus*: Report of a clinical failure. Antimicrob. Agent Chemother., 49: 1222-1224.

Lim, A., A.E. Kwon, S.K. Kim, Y. Cong, K. Lee and E.C. Choli, 2002. Prevalence of resistance to macrolide and lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in Korean hospitals. J. Antimicrob. Chemother., 49: 489-49.

NCCLS, 2004. Performance standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards (NCCLS) Approved Standard M100-S14, Wayne, PA., USA.

Patel, M.K.B., Wates, S. Amoser, G.A. Cloud and C.J. Hoesley, 2006. Prevalence of inducible clindamycin resistance among community and hospital-associated *Staphylococcus aureus* isolates. J. Clin. Microbiol., 44: 2481-2484.

- Schreckenberger, P.C., E. Ilendo and K.L. Ristow, 2004. Incidence of constitutive and inducible clindamycin resistance in *Staphylococcus aureus* and coagulase-negative staphylococci in a community and tertiary care hospital. *J. Clin. Microbiol.*, 42: 2777-2779.
- Sibery, G.K., T. Tekle, K. Carrol and J. Dick, 2003. Failure of clindamycin treatment of methicillin-resistant *Staphylococcus aureus* expressing inducible clindamycin resistance *in vitro*. *Clin. Infect. Dis.*, 37: 1 1227-1260.
- Steward, C.D., P.M. Raney, A.K. Morrel, P.P. William and L.K. McDougal *et al.*, 2005. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of *Staphylococcus aureus*. *J. Clin. Microbiol.*, 43: 1716-1723.
- Zelazny, A.M., M.J. Ferraro, A. Glennen, J.F. Hindler and L.M. Mann *et al.*, 2005. Selection of strains for quality assessment of disk induction method for detection of inducible clindamycin resistance in Staphylococci: A CLSI collaborative study. *J. Clin. Microbiol.*, 43: 2613-2615.